Investigating a new inflammatory marker's link to fatty liver disease and liver fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the relationship between a novel inflammatory marker, the high-sensitivity C-reactive protein to albumin ratio (hsCAR), and metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis. Utilizing data from the National Health and Nutrition Examination Survey (NHANES) from 2017 to 2020, the study will assess liver steatosis and fibrosis severity through ultrasonic indices. The researchers will employ multivariate logistic regression analysis and subgroup analyses to determine if hsCAR can serve as a clinical indicator for diagnosing MAFLD and identifying liver fibrosis in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Total participants from NHANES 2017-2020
* Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.

  1. Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).
  2. Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians
  3. If presence of at least two metabolic risk abnormalities:

     * Waist circumference≥102/88 cm in Caucasian men and women (or≥90/80 cm in Asian men and women)
     * Blood pressure≥130/85 mmHg or specific drug treatment
     * Plasma triglycerides≥150 mg/dl (≥1.70 mmol/L) or specific drug treatment
     * Plasma HDL-cholesterol \<40 mg/dl (\<1.0 mmol/L) for men and \<50 mg/dl (\<1.3 mmol/L) for women or specific drug treatment
     * Prediabetes (i.e., fasting glucose levels 100 to 125 mg/dl \[5.6 to 6.9 mmol/L\], or 2-hour post-load glucose levels 140 to 199 mg/dl \[7.8 to 11.0 mmol\] or HbA1c 5.7% to 6.4% \[39 to 47 mmol/mol\])
     * Homeostasis model assessment of insulin resistance score≥2.5
     * Plasma high-sensitivity C-reactive protein level \>2 mg/L

Exclusion Criteria:

* Liver ultrasound data not available
* participants without complete clinical data
* participants under 18 years old
* participants with cancer.

Where it's running

• The Second Affiliated Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Tingqiu Wang, Bachelor
• Email: w857683014@163.com
• Phone: +8617815370539

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• Umbilical cord stem cells added during Kasai to help biliary atresia

  This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta · NCT07797673

• Pre-hepatectomy rehabilitation with mazdutide for obese MASLD donors

  This trial tests whether adding mazdutide to a structured lifestyle plan helps overweight MASLD donors lose liver fat faster to become eligible for donation.

  Recruiting Phase 4 West China Hospital · Hefei, Anhui and 3 other locations · NCT07718126

• Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD

  This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07658755

• Liver Inflammation Index test for MASH in adults with T2DM and MAFLD

  This study tests a Liver Inflammation Index to see if it can identify MASH in adults who have both type 2 diabetes and MAFLD.

  Recruiting at 22 sites The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Bengbu, Anhui and 21 other locations · NCT07632677

• AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring

  This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.

  Recruiting at 22 sites Phase 2 AstraZeneca · Chandler, Arizona and 21 other locations · NCT07610837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.